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AbstrAct
Objective To examine the association between 
antidepressant use and weight gain, as well as the 
interaction with lifestyle factors.
Design Longitudinal study.
setting and participants We used data from 2334 
adults from two stages (4.4 years apart) of the North 
West Adelaide Health Study, including validated diet and 
lifestyle questionnaires, measured body weight and linked 
pharmaceutical prescription data.
Main outcome measures Body weight change.
results 188 (8.1%) participants had a mean annual 
number of 1–2 antidepressant prescriptions, and 212 
(9.1%) had over two prescriptions. The mean annual 
weight gain was 0.12, 0.18 and 0.28 kg in non-users, 
low (1–2 prescriptions/year) and high (>2 prescriptions/
year) antidepressant users, respectively. In multivariable 
regression models, antidepressant use was positively 
associated with weight gain: high antidepressant users 
gained an extra 0.22 (95% CI 0.00 to 0.44) kg per year. 
This association was mainly due to selective serotonin 
reuptake inhibitor (SSRI) use. High SSRI users gained 0.48 
(95% CI 0.20 to 0.76) kg more than non-users. There was 
no association between tricyclic or other antidepressant 
use and weight gain. The association between SSRI use 
and weight gain was stronger among those with high 
intake of Western diet, greater sedentary activity, and who 
smoked.
conclusions SSRIs use was associated with weight gain 
in the presence of unhealthy behaviours including Western 
diet, sedentarism and smoking.
IntrODuctIOn
Obesity is a major global health problem 
almost entirely caused by excess dietary 
intake and reduced energy expenditure. It 
is estimated that up to 205 million men and 
297 million women over the age of 20 world-
wide are obese.1 In Australia, the prevalence 
of obesity class I (body mass index (BMI) 
30–34.9 kg/m2) and obesity class II or III 
(BMI ≥35 kg/m2) has respectively doubled 
and almost tripled since 1980.2 Currently it 
is estimated that 28.3% of Australian adults 
are obese.3 One of the most important health 
consequences of high and rising trends 
in global obesity prevalence has been the 
increased risk of developing depression.4 
Indeed, data from the Global Burden of 
Disease study suggest that major depres-
sive disorder was the second leading cause 
accounting for 8.2% of global years lived with 
disability in 2010.5
Several population-based cohort studies 
have consistently shown a positive relation-
ship between antidepressant use and weight 
gain in countries such as the USA,6–8 Canada9 
and Australia.10 This is valuable informa-
tion for public health policy-makers and 
researchers given that the prevalence of anti-
depressant use is high in Australia and the 
USA (5%–12%),7 11 and frequently used by 
people without depressive or anxiety disor-
ders.12
The underlying cause of weight gain due 
to long-term antidepressant use is poorly 
understood.13 In rodents, data from our labo-
ratory have shown that the combination of 
chronic stress and short-term antidepressant 
treatment, followed by high-fat diet, results 
in long-term weight gain that is greater 
than that caused by stress and high-fat diet, 
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Research
strengths and limitations of this study
 ► Measurement of body weight by health workers at 
both time points with a mean of 4.4 years of follow-
up;
 ► Ability to adjust for detailed lifestyle factors and 
chronic conditions;
 ► The total number of antidepressant users was 
relatively small, which limited our power to conduct 
detailed subgroup analyses;
 ► Dietary intake was only assessed at follow-up; 
therefore, we were unable to adjust for dietary 
change during follow-up.
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without antidepressant exposure.14 In our animal para-
digm, antidepressant exposure potentiated weight gain 
caused by obesity-promoting diet. Thus, increased anti-
depressant exposure might be a contributory factor to 
the obesity pandemic.13 It is supported by the change of 
energy intake related to antidepressant use. Data from a 
recent cross-sectional population-based study showed that 
antidepressant use was associated with increased energy 
intake.15 Poor diet, sedentary lifestyle, obesity and depres-
sion often cluster together; however, association studies 
between antidepressant use and obesity have been mostly 
based on registry data or short-term clinical trials, which 
limit their use to understand interactions.6–10 Therefore, 
whether specific antidepressant medications interaction 
with lifestyle risk factors (poor diet, inadequate physical 
activity and smoking) partially explain the development 
of human obesity is still unclear. Identifying the potential 
mechanism by which antidepressant medication increases 
the risk of obesity could help develop targeted strategies 
for prevention.
This study was designed to specifically examine the asso-
ciation between antidepressant use and weight gain, as 
well as the interaction with diet and other lifestyle factors 
(eg, smoking, sedentary activity) in adults participating in 
a large-population based prospective cohort study.
MethODs
Data source and study participants
This study was approved by the Queen Elizabeth Hospital 
Human Research Committee and, where appropriate, 
by the Aboriginal Health Research Ethics Committee, 
Adelaide, South Australia, Australia. The North West 
Adelaide Health Study (NWAHS) is an ongoing commu-
nity-based cohort study among adults living in the North 
West region of Adelaide, South Australia. A detailed 
description of this cohort has been published elsewhere.16 
The current study analysed data from both stage 2 (2004–
2006) and stage 3 (2008–2010) data collections. A total 
of 2334 participants had information on body weight at 
both time points.
Outcome variable—change in body weight
At both stages 2 and 3, height and body weight were 
measured in light clothing and without shoes by trained 
clinic staff, to the nearest 0.1 cm and 0.1 kg, respectively. 
Annual weight gain was calculated by the difference of 
body weight (kg) between follow-up and baseline divided 
by the duration of follow-up (in years). Overweight 
and obesity were defined respectively as 25 kg/m2≥ 
BMI <30 kg/m2 and BMI ≥30 kg/m2.
exposure variable—prospective antidepressant use
Information on medication use (based on prescrip-
tion) according to the Anatomical Therapeutic 
Chemical (ATC) Classification was obtained from Medi-
care Australia (Pharmaceutical Benefits Scheme (PBS)) 
by confidential unit record linkage for the study period 
(between baseline and follow-up). Antidepressants (ATC 
code N06A) were categorised into three groups: tricyclic 
antidepressants (TCAs) (ATC code N06AA), selective 
serotonin reuptake inhibitors (SSRIs) (ATC code N06AB) 
and other antidepressants (ATC code N06AF, N06AG and 
N06AX). For each participant, the mean annual number 
of antidepressant prescriptions, calculated by adding the 
number of prescriptions and dividing it by the follow-up 
duration between stages 2 and 3, was categorised into 
three groups: non-user, low user (1–2 prescriptions/year) 
or high user (>2 prescriptions/year). Exposure of specific 
antidepressants was assessed independent of one or more 
antidepressants.
covariates
Baseline and follow-up covariates
The Centre for Epidemiologic Studies Depression Scale 
(CES-D) was used to measure depressive symptoms. 
CES-D scores were categorised as no depression (<16), 
mild depression (16-26) or moderate to severe depression 
(>26).17 Smoking behaviour was determined by self-re-
port and coded as (1) non-smoker and (2) current or 
ex-smoker. Self-reported income was recoded into three 
levels (<$A20 000, $A20 000-$A60 000 or >$A60 000). 
Physical activity questions (baseline) from the Australian 
National Health Surveys were used to classify participants 
as sedentary, or having low, moderate or high levels of 
physical activity.18 Respondents were asked about the 
amount of walking, moderate and vigorous activity they 
had undertaken in the past 2 weeks.
Follow-up only covariates
Dietary intake during the previous 12 months was assessed 
by the Cancer Council Victoria Dietary Questionnaire 
for Epidemiological Studies V3.1 (modification of Food 
Frequency Questionnaire (FFQ)). The FFQ was previ-
ously validated in an Australian population, and is widely 
used in epidemiological studies. In the analysis, the daily 
intake of 128 food items were collapsed into 41 food 
groups as previously described.19 Dietary patterns were 
identified by factor analysis using the principal compo-
nent method. Varimax rotation was used to assist the 
interpretability of the factor solution. Based on the Eigen-
value (>1), scree plot and interpretability, two dietary 
patterns were constructed: (1) the prudent pattern was 
characterised by high loadings of fruit and vegetable (see 
online supplementary figure S1) and (2) the Western 
pattern had high intake of processed meat, snacks and 
fast food. Scores of each dietary pattern were calculated 
as the sum of the products of factor loading coefficients 
and standardised daily intake of the food intake. Dietary 
pattern scores were dichotomised as low and high (ie, 
below or above zero).
statistical analyses
Analysis of variance and χ2 test were used respectively to 
compare differences between categorical variables and in 
continuous variables between groups (gender, categories 
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of antidepressant use). Linear regression models were 
used to assess the longitudinal association between anti-
depressant use and annual weight change. Three models 
were employed: model 1 was adjusted for age and gender, 
model 2 was further adjusted for income, smoking, phys-
ical activity and follow-up duration, and model 3 was 
further adjusted for depression status at baseline and 
follow-up and dietary patterns (continuous). Participants 
with missing information of depression were excluded in 
the corresponding analyses.
As the association between antidepressant use and 
weight gain was mainly due to SSRI, we further looked 
at the interaction between SSRI use and lifestyle factors. 
Multiplicative interaction between SSRI use, lifestyle 
factors (categorical variables of dietary patterns (low or 
high), smoking (non-smoker, current or ex-smoker) and 
physical activity (sedentary, low, moderate/high)) was 
conducted by inputting the product terms of these vari-
ables and antidepressant use in the regression models. 
The analysis was subsequently stratified for lifestyle 
factors. The interaction between antidepressant use and 
age (continuous) was graphically represented using the 
marginsplot command in STATA V.14 (Stata Corpora-
tion).
Sensitivity analyses were conducted using mixed linear 
modelling to assess the association between antide-
pressant use and body weight (baseline and follow-up), 
adjusted for age, income, depression and smoking status 
as time-varying variables, while considering antidepres-
sant use, physical activity, dietary patterns and gender as 
time-invariant variables. We also assessed the association 
(incident rate ratio) between antidepressant use and 5% 
weight gain over 5 years using Poisson regression with 
robust variance.
All analyses were performed using STATA V.14, and 
statistical significance was set at p<0.05 (two sided).
results
The mean age of the sample was 54.1 (SD 14.1) years 
(table 1). The mean duration of follow-up was 4.4 (SD 
0.4) years. Women had a higher prevalence of depres-
sion and a higher mean level of antidepressant use than 
men. In the sample, 188 (8.1%) and 212 (9.1%) partici-
pants had a mean annual number of 1–2, and more than 
2 antidepressant prescriptions, respectively. Information 
on antidepressant usage was based on prescription infor-
mation; out of 400 antidepressant users, 225 (56.3%) 
were SSRI users, and in high SSRI users the mean annual 
number of SSRI prescriptions was 5.9 (SD 3.1) (see online 
supplementary table S1). The mean annual weight gain 
was 0.12, 0.18 and 0.28 kg in non-users, low and high anti-
depressant users, respectively.
Compared with non-users, high antidepressant users 
had higher energy intake (9160 vs 8628 kJ/day) and 
higher Western dietary pattern scores after adjusting for 
age and gender (see online supplementary table S2).
In multivariable regression models adjusted for age, 
gender, income, smoking, physical activity, follow-up 
duration and dietary patterns, antidepressant use was 
positively associated with weight gain. High users gained 
0.22 kg (95% CI 0.00 to 0.44) per year when compared 
with non-users, and SSRI use was related to weight gain 
(table 2). In the fully adjusted model, high SSRI users 
gained 0.48 kg (95%CI 0.20 to 0.76) more than non-users. 
No association was found between TCA and other antide-
pressant use and weight gain.
In relation to annual weight gain, significant interac-
tions were found between SSRI use and three lifestyle 
factors: Western dietary pattern, smoking and sedentary 
activity (table 3). The association between SSRI use and 
weight gain was mainly seen among those with unhealthy 
lifestyle; a strong dose–response relationship between 
SSRI use and weight gain was observed among those with 
high intake of Western diet: the regression coefficients 
were 0.00 kg, 0.46 kg (95% CI 0.05 to 0.88) and 0.84 
kg (95%CI 0.43 to 1.24) for non-users, low users and high 
users, respectively. This association was not seen in those 
with low intake of Western diet. No significant interaction 
between SSRI use and the prudent dietary pattern was 
found. Among those with sedentary lifestyles, high SSRI 
use was associated with 1.01 kg (95%CI 0.52 to 1.50) higher 
weight gain per year than non-users. A consistent positive 
association between SSRI use and weight gain was only 
observed among smokers: low and high SSRI use was 
respectively associated with 0.44 kg (95% CI 0.05 to 0.84) 
and 0.66 kg (95% CI 0.23 to 1.10) higher weight gain per 
year than non-users.
There was a significant interaction between antidepres-
sant use and age in relation to weight gain (see online 
supplementary figure S2). The positive association 
between high antidepressant use and weight gain was 
mainly seen among those aged below 50 years.
In the multivariable mixed regression model adjusted 
for time-varying depression status, smoking, age and 
income as well as time-invariant dietary patterns, phys-
ical activity and gender, antidepressant use was associated 
with body weight (baseline and follow-up)(see online 
supplementary table S3). Compared with non-use, high 
use was associated with an extra body weight of 4.40 kg 
(any antidepressant, p=0.002), 4.20 kg (SSRI, p=0.007) 
and 7.14 kg (other antidepressant, p<0.001), respectively. 
TCA use was not associated with body weight. No interac-
tion between antidepressant use and gender was found 
(data not shown).
Overall, 27.2% of the participants had weight gain above 
5% over 5 years. In fully adjusted model, the incident rate 
ratio (IRR) for 5% weight gain were 1.00, 1.09 (95% CI 
0.83 to 1.44) and 1.37 (95% CI 1.10 to 1.70) for non-users, 
low users and high users of antidepressant, respectively. A 
dose–response association between SSRI use and 5% weight 
gain was found in fully adjusted model: IRRs were 1.00, 1.37 
(95% CI 1.03 to 1.81) and 1.43 (95% CI 1.10 to 1.86) (p 
trend <0.001) for non-users, low users and high users of 
SSRI, respectively (data not shown).
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Table 1 Sample characteristic by sex*
Male Female Total p Value
n (%) 1095 (46.9) 1239 (53.1) 2334
Age (years) 54.0 (14.4) 54.3 (13.8) 54.1 (14.1) 0.648
Baseline weight (kg) 87.2 (15.3) 73.5 (16.1) 79.9 (17.2) <0.001
Follow-up weight (kg) 87.9 (16.0) 74.0 (16.2) 80.5 (17.5) <0.001
Annual weight gain (kg) 0.17 (1.35) 0.12 (1.46) 0.14 (1.41) 0.449
Baseline BMI status
  Normal 21.9 34.5 28.6 <0.001
  Overweight 48.9 34.2 41.1
  Obese 29.2 31.2 30.3
Baseline income ($)
  <20 000 196 (17.9) 332 (26.9) 528
  20 000–60000 529 (48.4) 543 (44.0) 1072
  >60 000 338 (31.0) 308 (24.9) 646
  Not stated 29 (2.7) 52 (4.2) 81 <0.001
Baseline smoking status
  Non-smoker 444 (40.7) 642 (52.0) 1086
  Current or ex-smoker 647 (59.3) 593 (48.0) 1240 <0.001
Baseline physical activity
  Sedentary 252 (25.9) 345 (30.4) 597
  Low exercise level 323 (33.2) 448 (39.5) 771
  Moderate exercise level 291 (29.9) 285 (25.1) 576
  High exercise level 106 (10.9) 56 (4.9) 162 <0.001
Depression (baseline)
  No depressive symptoms 995 (91.3) 1043 (85.4) 2038
  Mild depression 61 (5.6) 122 (10.0) 183
  Moderate to severe depression 34 (3.1) 56 (4.6) 90 <0.001
Depression (follow-up)
  No depressive symptoms 907 (85.6) 958 (79.6) 1865
  Mild depression 101 (9.5) 151 (12.5) 252
  Moderate to severe depression 52 (4.9) 95 (7.9) 147 <0.001
Any antidepressant † 0.4 (1.7) 0.9 (2.5) 0.7 (2.2) <0.001
TCAs † 0.1 (0.6) 0.2 (1.3) 0.1 (1.0) <0.001
SSRIs † 0.2 (1.3) 0.4 (1.6) 0.3 (1.4) 0.019
Other antidepressant † 0.1 (0.8) 0.3 (1.5) 0.2 (1.2) <0.001
*Values are n (%) or mean (SD).
†Annual number of prescriptions.
BMI, body mass index; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
DIscussIOn
In this prospective study, we found that antidepressant 
use was positively associated with weight gain, which 
was influenced by significant interactions between 
SSRI use, age, and unhealthy lifestyle factors, including 
western dietary pattern, sedentary activity and smoking.
The mean annual weight gain among antidepressant 
users during this 4.4-year study was around 0.2 kg, which 
is similar to those reported in the literature for shorter 
studies.6 7 9 10 20 However, in those previous population 
studies, lifestyle factors were either lacking or treated as 
confounding factors.6 7 9 10 20 None of those studies had 
been adjusted for dietary intake, an important factor for 
weight gain.
Only one previous study assessed differences in energy 
intake and physical activity between antidepressant users 
and non-users, employing data from the 2005–2006 
National Health and Nutrition Examination Survey. It 
showed that, after adjusting for potential confounding 
factors, antidepressant users had an extra 215 kcal/
day of energy intake and were 77% more likely to use a 
computer for ≥2 hour/day than non-users.15 The authors 
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Table 2 Association (β 95% CI) between antidepressant use and annual weight gain
Non-user 1–2 prescriptions/year >2 prescriptions/year p Value
Any antidepressant
  n 1934 188 212
  Baseline weight (kg), mean (SD) 80.0 (17.0) 77.1 (16.5) 81.3 (19.1)
  Follow-up weight (kg), mean (SD) 80.6 (17.3) 78.0 (17.2) 82.5 (19.6)
  Annual weight change (kg), mean (SD) 0.12 (1.32) 0.18 (1.54) 0.28 (1.99)
   Model 1* Ref 0.15(−0.06 to 0.36) 0.22 (0.02 to 0.42) 0.022
   Model 2† Ref 0.18(−0.04 to 0.40) 0.25 (0.04 to 0.46) 0.009
   Model 3‡ Ref 0.11(−0.11 to 0.34) 0.22 (0.00 to 0.44) 0.044
SSRIs
  n 2109 114 111
  Baseline weight (kg), mean (SD) 79.8 (17.0) 79.7 (18.2) 82.2 (19.1)
  Follow-up weight (kg), mean (SD) 80.3 (17.3) 81.2 (18.0) 84.9 (21.2)
  Annual weight change (kg), mean (SD) 0.11 (1.33) 0.38 (2.11) 0.61 (1.89)
   Model 1* Ref 0.30 (0.04 to 0.57) 0.53 (0.27 to 0.80) <0.001
   Model 2† Ref 0.30 (0.03 to 0.58) 0.58 (0.30 to 0.85) <0.001
   Model 3‡ Ref 0.30 (0.01 to 0.58) 0.48 (0.20 to 0.76) <0.001
TCAs
  n 2212 79 43
  Baseline weight (kg), mean (SD) 80.1 (17.2) 76.3 (17.8) 77.3 (15.9)
  Follow-up weight (kg), mean (SD) 80.8 (17.5) 75.5 (17.3) 77.3 (16.4)
  Annual weight change (kg), mean (SD) 0.16 (1.40) −0.13 (1.61) −0.01 (1.32)
   Model 1* Ref −0.12(−0.44 to 0.19) 0.06(−0.36 to 0.49) 0.717
   Model 2† Ref −0.11(−0.44 to 0.22) 0.05(−0.39 to 0.50) 0.704
   Model 3‡ Ref 0.02(−0.31 to 0.36) 0.03(−0.46 to 0.52) 0.908
Other antidepressants
  n 2210 57 67
  Baseline weight (kg), mean (SD) 79.8 (17.0) 80.0 (18.7) 82.9 (20.5)
  Follow-up weight (kg), mean (SD) 80.4 (17.4) 81.3 (17.6) 83.4 (21.2)
  Annual weight change (kg), mean (SD) 0.14 (1.37) 0.35 (1.88) 0.12 (2.08)
   Model 1* Ref 0.23(−0.13 to 0.60) −0.04(−0.38 to 0.29) 0.844
   Model 2† Ref 0.32(−0.05 to 0.70) −0.01(−0.36 to 0.35) 0.505
   Model 3‡ Ref 0.42 (0.03 to 0.80) −0.19(−0.56 to 0.19) 0.926
*Model 1 adjusted for age and gender.
†Model 2 further adjusted for baseline income, smoking, physical activity, follow-up duration.
‡Model 3 further adjusted for depression status at baseline and follow-up, dietary patterns (continuous).
SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
hypothesised that increased energy intake and sedentary 
activity could contribute to weight gain associated with 
antidepressant use. In the present study, we also found 
a significant difference in energy intake between high 
antidepressant users and non-users. After adjusting for 
age and gender, high antidepressant users had a higher 
energy intake than non-users (9160 vs 8628 kJ/day). 
Furthermore, high antidepressant users had higher 
Western dietary pattern scores than non-users (0.14 
vs −0.03). To the best of our knowledge, this is the first 
study that systematically tested the interactions between 
antidepressant use and modifiable lifestyle factors. A 
significant positive dose–response association between 
antidepressant use and weight gain was found in indi-
viduals with high intake but not in those with low intake 
of Western diet. Clustering of unhealthy behaviours 
and chronic diseases, including depression, may partly 
explain the interaction between unhealthy lifestyle and 
weight gain among those using antidepressant.
The interaction between antidepressant use and 
smoking in relation to weight gain was consistent 
with that reported by Arterburn et al who found that 
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Table 3 Subgroup analyses of the association between SSRI use and annual weight gain*
Non-user 1–2 prescriptions/year >2 prescriptions/year p For interaction
Western dietary pattern 0.026
  Low intake 0.00 0.11(−0.29–0.51) 0.14(−0.26–0.54)
  High intake 0.00 0.46 (0.05–0.88)† 0.84 (0.43–1.24)
Prudent dietary pattern 0.635
  Low intake 0.00 0.35(−0.07–0.78) 0.38(−0.02–0.78)
  High intake 0.00 0.23(−0.16–0.63) 0.61 (0.20–1.02)
Physical activity 0.039
  Sedentary 0.00 0.15(−0.34–0.63) 1.01 (0.52–1.50)
  Low 0.00 0.34(−0.13–0.82) 0.23(−0.27–0.72)
  Moderate/high 0.00 0.33(−0.27–0.94) 0.06(−0.49–0.61)
Smoking 0.002
  Non-smoker 0.00 −0.28(−0.73–0.16) 0.35(−0.03–0.72)
  Current or ex-smoker 0.00 0.44 (0.05–0.84) 0.66 (0.23–1.10)
*Bold values represent p<0.05.
†Models adjusted for age, gender, income, physical activity, smoking, depression status at baseline and follow-up. Stratifying variables 
were not adjusted in the corresponding models. Dietary pattern scores are dichotomised as low or high intake. Values represent regression 
coefficients (95% CI).
SSRI, selective serotonin reuptake inhibitor.
bupropion-treated smokers gained an extra 6.44 kg 
compared with fluoxetine-treated non-smokers during a 
2-year follow-up study.8 We observed an intriguing inter-
action between antidepressant use and age in relation to 
weight gain, which may be related to the fact that younger 
people are more likely to eat a Western diet. In our 
sample, age was inversely associated with Western dietary 
pattern scores (data not shown).
The lack of association between TCA use and weight 
gain was also reported in the Netherlands Study of Depres-
sion and Anxiety, as well as the Rotterdam Study.20 21 
However, previous studies have reported an association 
between TCA use and weight gain.6 13 Our null association 
between TCA use and weight gain may be due to the fact 
that age was positively associated with TCA use (p<0.001). 
The mean age was respectively 53.6, 62.2 and 65.6 years 
among non-users, low and high users of TCA (data not 
shown). The SSRI fluoxetine entered medical use in 
1986; TCAs were the gold standard for depression treat-
ment before SSRIs became popular. It is likely that older 
patients started their treatment with TCA and those that 
were treated with and responded to TCAs for many years 
before SSRIs became available may have been reluctant 
to be switched to SSRIs. However, there was no signifi-
cant age difference between SSRIs users and non-users. 
Another explanation could be that doctors may be more 
likely to prescribe SSRIs to people who are worried about 
weight gain as TCA use has been linked to weight gain in 
clinical trials.
The strengths of this study include: (1) measurement 
of body weight by health workers at both time points with 
a mean of 4.4 years of follow-up; (2) ability to adjust for 
detailed lifestyle factors and chronic conditions. The main 
limitation of the study compared with other registry-based 
studies was that the total number of antidepressant users 
was relatively small, which limited our power to conduct 
detailed subgroup analyses. The effect size of the anti-
depressant use on weight gain may be underestimated 
due to the fact that some of the low-cost antidepres-
sants (below copayment level) were not recorded by the 
PBS system before 2012. The PBS dataset only provides 
information on dispensing not the actual use of antide-
pressants. Furthermore, dietary intake was only assessed at 
follow-up; therefore, we were unable to adjust for dietary 
change during follow-up. There may also be an underes-
timate or overestimate of energy intake due to the use of 
FFQ and the inherent issues surrounding recall. Finally, 
the sample power may be limited for the analyses of TCA 
and other antidepressants.
Antidepressants are widely used, representing the 
most prescribed drug class in the USA22; in Australia 
11.6% of the country’s population is on antidepres-
sants.23 Antidepressant-related weight gain is an 
outcome of public health relevance, as it may contribute 
to increased rates of obesity. Here, we provide evidence 
that antidepressant use was associated with weight 
gain, especially among those with unhealthy lifestyles, 
resulting in body weight that is higher than that asso-
ciated solely with those same lifestyle factors, in the 
absence of antidepressants. As a matter of public 
health relevance, SSRI use should be accompanied by 
proactive efforts to avoid weight gain. We suggest that 
reducing Western diet consumption, increasing physical 
activity and smoking cessation may mitigate antidepres-
sant-related weight gain. General practitioners should 
encourage their patients to adopt healthy lifestyle while 
group.bmj.com on April 12, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Shi Z, et al. BMJ Open 2017;7:e016224. doi:10.1136/bmjopen-2017-016224
Open Access
treating depression with antidepressants or cogni-
tive behavioural therapy.
contributors ZS contributed to the conception, analysis and interpretation of data; 
drafting of the report and have given approval of the final version for publication. 
EA, AWT, TKG, KP, SA, MLW and JL contributed to analysis and interpretation of the 
data, commented on the report, revising the manuscript and approving the final 
version for publication.
competing interests None declared.
Patient consent Obtained.
ethics approval Queen Elizabeth Hospital Human Research Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data from the North West Adelaide Healthy Study 
(NWAHS) were accessed from a third party. The authors confirm that for approved 
reasons, some access restrictions apply to the data underlying the findings. To gain 
access to the data for this manuscript, ethics approval was sought and granted. 
Enquiries regarding requests for the NWAHS data can be directed to Prof Robert 
Adams, Principal Investigator (Clinical) ( robert. adams@ adelaide. edu. au).
Open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
references
 1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and 
global trends in body-mass index since 1980: systematic analysis 
of health examination surveys and epidemiological studies with 960 
country-years and 9·1 million participants. Lancet 2011;377:557–67.
 2. Atlantis E, Lange K, Wittert GA. Chronic disease trends  
due to excess body weight in Australia. Obes Rev  
2009;10:543–53.
 3.  Australian Bureau of Statistics. 4364.0.55.001 - Australian Health 
Survey: FirstResults 2011-12. 2012.
 4. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and 
depression: a systematic review and meta-analysis of longitudinal 
studies. Arch Gen Psychiatry 2010;67:220–9.
 5. Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive 
disorders by country, sex, age, and year: findings from the  
global burden of disease study 2010. PLoS Med  
2013;10:e1001547.
 6. Kivimäki M, Hamer M, Batty GD, et al. Antidepressant medication 
use, weight gain, and risk of type 2 diabetes: a population-based 
study. Diabetes Care 2010;33:2611–6.
 7. Blumenthal SR, Castro VM, Clements CC, et al. An electronic health 
records study of long-term weight gain following antidepressant use. 
JAMA Psychiatry 2014;71:889–96.
 8. Arterburn D, Sofer T, Boudreau DM, et al. Long-term weight change 
after initiating second-generation antidepressants. J Clin Med 
2016;5:48.
 9. Patten SB, Williams JV, Lavorato DH, et al. Weight gain in relation to 
major depression and antidepressant medication use. J Affect Disord 
2011;134(1-3):288–93.
 10. Paige E, Korda R, Kemp-Casey A, et al. A record linkage study of 
antidepressant medication use and weight change in Australian 
adults. Aust N Z J Psychiatry 2015;49:1029–39.
 11. Atlantis E, Sullivan T, Sartorius N, et al. Changes in the prevalence 
of psychological distress and use of antidepressants or anti-anxiety 
medications associated with comorbid chronic diseases in the 
adult Australian population, 2001-2008. Aust N Z J Psychiatry 
2012;46:445–56.
 12. Harris MG, Burgess PM, Pirkis J, et al. Correlates of antidepressant 
and anxiolytic, hypnotic or sedative medication use in an Australian 
community sample. Aust N Z J Psychiatry 2011;45:249–60.
 13. Lee SH, Paz-Filho G, Mastronardi C, et al. Is increased 
antidepressant exposure a contributory factor to the obesity 
pandemic? Transl Psychiatry 2016;6:e759.
 14. Mastronardi C, Paz-Filho GJ, Valdez E, et al. Long-term body 
weight outcomes of antidepressant-environment interactions. Mol 
Psychiatry 2011;16:265–72.
 15. Jensen-Otsu E, Austin GL. Antidepressant use is associated with 
increased energy Intake and similar levels of physical activity. 
Nutrients 2015;7:9662–71.
 16. Grant JF, Taylor AW, Ruffin RE, et al. Cohort profile: the North West 
Adelaide Health Study (NWAHS). Int J Epidemiol 2009;38:1479–86.
 17. Radolff LS. The CES-D scale: a self-report depression scale 
for research in the general population. Applied Psychological 
Measurement 1977;1:385–401.
 18. Australian Bureau of Statistics. editor, National Health Survey: Users' 
Guide. Canberra: ABS, 2003.
 19. Schoenaker DA, Dobson AJ, Soedamah-Muthu SS, et al. Factor 
analysis is more appropriate to identify overall dietary patterns 
associated with diabetes when compared with treelet transform 
analysis. J Nutr 2013;143:392–8.
 20. Gibson-Smith D, Bot M, Milaneschi Y, et al. Major depressive 
disorder, antidepressant use, and subsequent 2-year weight change 
patterns in the Netherlands Study of Depression and Anxiety. J Clin 
Psychiatry 2016;77:e144–e151.
 21. Noordam R, Aarts N, Tiemeier H, et al. Sex-specific association 
between antidepressant use and body weight in a population-based 
study in older adults. J Clin Psychiatry 2015;76:e745–e751.
 22. IMS Institute for Healthcare Informatics. The use of medicines in the 
United States: review of 2011, 2012.
 23. Mental Health Services in Australia. Mental health-related 
prescriptions. Secondary mental health-related prescriptions. https:// 
mhsa. aihw. gov. au/ resources/ prescriptions/
group.bmj.com on April 12, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
study
results from a 4-year Australian follow-up
gain in the context of unhealthy lifestyles: 
SSRI antidepressant use potentiates weight
Appleton, Ma-Li Wong and Julio Licinio
Zumin Shi, Evan Atlantis, Anne W Taylor, Tiffany K Gill, Kay Price, Sarah
doi: 10.1136/bmjopen-2017-016224
2017 7: BMJ Open
 http://bmjopen.bmj.com/content/7/8/e016224




This article cites 19 articles, 2 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (2430)Public health





To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on April 12, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
